Connect
← Return to Boehringer Ingelheim AIRTIVITY clinical trial
Discussion
Boehringer Ingelheim AIRTIVITY clinical trial
MAC & Bronchiectasis | Last Active: Jun 15 9:57am | Replies (55)Comment receiving replies
My understanding is that Airtivity is a DPP1 inhibitor similar to brensocatib but with different mechanism of action. It's a ways out for trial completion, 2028. Sigh.
Replies to "My understanding is that Airtivity is a DPP1 inhibitor similar to brensocatib but with different mechanism..."
Connect
But if you enroll you might be on the drug for the length of the trial. And probably after as well. That was the case for brensocatib. Even if you were on the placebo, you were giving me the option after completing the trial to go on the drug. I know someone in New Zealand, who was on the drug during the trial and then continued. For her, it was life-changing.